MAY 07, 2020 6:16 AM PDT

New COVID-19 Vaccine Defends Monkeys Against Infection

WRITTEN BY: Tara Fernandez

Researchers from Beijing-based Sinovac Biotech have reported preliminary results of a study into the development of a vaccine against COVID-19. This is some of the first evidence of a vaccine showing efficacy in a primate experimental model (rhesus macaques) and provides hope for a global community anxiously awaiting countermeasures against the escalating pandemic.

Experts estimate that a clinically-available vaccine against SARS-CoV-2 could take 18 months or longer to develop, even at an accelerated pandemic pace. A new vaccine needs to be thoroughly tested for safety and efficacy in animals and humans prior to its commercialization. Before phase I testing, in which a small group of healthy volunteers receives the vaccine in development, vaccines are typically tested in non-human primates, which share physiological and disease process similarities with humans.

In Sinovac’s study, the vaccine testing protocol involved two doses of inactivated SARS-CoV-2, administered to a cohort of eight rhesus monkeys. The animals were allowed to develop a natural immune response to the inactivated virus over the course of three weeks. They were then exposed to live, unadulterated SARS-CoV-2 to test the protective capabilities of the vaccine treatment.

Encouragingly, none of the monkeys experienced the symptoms of severe infection, nor had any unwanted side-effects as a result of the shot. Meanwhile, the control animals developed pneumonia and high levels of circulating virus as a result of exposure to the coronavirus.

In response to these findings, Florian Krammer, a virologist based at the  Icahn School of Medicine at Mount Sinai said, “This is old school but it might work. What I like most is that many vaccine producers, also in lower–middle-income countries, could make such a vaccine.”

While promising, experts warn that preclinical validation of a new vaccine will involve much more work: larger testing cohorts to provide statistical significance and testing protection against viral strains that specifically infect humans and escape variant strains.

Sinovac has already launched phase I human trials of its vaccine in China to evaluate the safety and degree of protection in over 100 volunteers. If these clinical trials go as planned, phase II studies will kick off in mid-May in a larger group of over 1,000 individuals.

 


Source: Science.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAR 18, 2020
Immunology
MAR 18, 2020
Immune cells can ease chronic pain
In the words of C.S. Lewis, “Pain insists upon being attended to.” This is especially true for patients suff ...
MAR 20, 2020
Neuroscience
MAR 20, 2020
The Little Things Matter: The Mental Impact of Social Distancing
Image: Metropolitian State University of Denver The COVID-19 pandemic has caused social interactions, resources, and mos ...
APR 02, 2020
Immunology
APR 02, 2020
Transforming T Cells into Powerful Memory Cells That Target Cancer
New cancer treatments are now based on harnessing the power of the human body’s own immune cells to get the job do ...
APR 06, 2020
Immunology
APR 06, 2020
Clearing the Path for Dendritic Cells to Eliminate Tumors
  Dendritic cells are the sentinels of the immune system and use their “tree-like” projections to prese ...
APR 16, 2020
Cancer
APR 16, 2020
The Unseen Barriers Surrounding Pancreatic Cancer
Pancreatic cancer is one of the deadliest cancers in the world. With a poor five year prognosis and lack of effective tr ...
APR 15, 2020
Immunology
APR 15, 2020
Why More Men than Women Die from COVID-19
As of April 9th, over 60% of deaths from COVID-19 in New York state were men. Meanwhile, as of April 6, 82% of patients ...
Loading Comments...